Terms: = Prostate cancer AND MALAT1, PRO1073, 378938, Q9UHZ2
48 results:
1. Beyond the genome: malat1's role in advancing urologic cancer care.
Imran M; Abida ; Eltaib L; Siddique MI; Kamal M; Asdaq SMB; Singla N; Al-Hajeili M; Alhakami FA; AlQarni AF; Abdulkhaliq AA; Rabaan AA
Pathol Res Pract; 2024 Apr; 256():155226. PubMed ID: 38452585
[TBL] [Abstract] [Full Text] [Related]
2. The Value of Combined Detection of Serum PSA, malat1 and TMPRSS2-ETV1 in Evaluating the Progress and Prognosis of prostate cancer.
Zhao G; Pan Z; Wang P
Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
[TBL] [Abstract] [Full Text] [Related]
3. New Molecular Markers for prostate cancer Diagnosis.
Amiri M; Asadi Samani L; Kashi AH; Khadem N; Ziaee SAM; Mowla SJ
Urol J; 2024 Feb; 21(1):1-13. PubMed ID: 37818554
[TBL] [Abstract] [Full Text] [Related]
4. Targeting malat1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in prostate cancer.
Yadav A; Biswas T; Praveen A; Ganguly P; Bhattacharyya A; Verma A; Datta D; Ateeq B
Cancer Res Commun; 2023 Oct; 3(10):2044-2061. PubMed ID: 37812088
[TBL] [Abstract] [Full Text] [Related]
5. Construction of lncRNA/Pseudogene-miRNA Network Based on In Silico Approaches for Glycolysis Pathway to Identify prostate Adenocarcinoma-Related Potential Biomarkers.
Khorsand M; Mostafavi-Pour Z; Tahmasebi A; Omidvar Kordshouli S; Mousavi P
Appl Biochem Biotechnol; 2024 Apr; 196(4):2332-2355. PubMed ID: 37542606
[TBL] [Abstract] [Full Text] [Related]
6. Modulation of long non-coding RNAs by resveratrol as a potential therapeutic approach in cancer: A comprehensive review.
Asemi R; Rajabpoor Nikoo N; Asemi Z; Shafabakhsh R; Hajijafari M; Sharifi M; Homayoonfal M; Davoodvandi A; Hakamifard A
Pathol Res Pract; 2023 Jun; 246():154507. PubMed ID: 37196467
[TBL] [Abstract] [Full Text] [Related]
7. Transcripts of the prostate cancer-Associated Gene
Metsälä O; Wahlström G; Taimen P; Kellokumpu-Lehtinen PL; Schleutker J
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674564
[TBL] [Abstract] [Full Text] [Related]
8. A Proteomic Approach Reveals That miR-423-5p Modulates Glucidic and Amino Acid Metabolism in prostate cancer Cells.
Luce A; Lombardi A; Ferri C; Zappavigna S; Tathode MS; Miles AK; Boocock DJ; Vadakekolathu J; Bocchetti M; Alfano R; Sperlongano R; Ragone A; Sapio L; Desiderio V; Naviglio S; Regad T; Caraglia M
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614061
[TBL] [Abstract] [Full Text] [Related]
9. Long noncoding RNA as a potential diagnostic tool for prostate cancer: a systematic review and meta-analysis.
Li Y; Wei C; Huang C; Ling Q; Zhang L; Huang S; Liao N; Liang W; Cheng J; Wang F; Mo L; Mo Z; Li L
Biomarkers; 2023 Feb; 28(1):1-10. PubMed ID: 36323640
[TBL] [Abstract] [Full Text] [Related]
10. METTL3-Mediated m
Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
[TBL] [Abstract] [Full Text] [Related]
11. LncRNA-malat1 Regulates cancer Glucose Metabolism in prostate cancer via MYBL2/mTOR Axis.
Mu X; Shen Z; Lin Y; Xiao J; Xia K; Xu C; Chen B; Shi R; Zhu A; Sun X; Tao T; Song X; Xuan Q
Oxid Med Cell Longev; 2022; 2022():8693259. PubMed ID: 35557985
[TBL] [Abstract] [Full Text] [Related]
12. NCAPD3 promotes prostate cancer progression by up-regulating EZH2 and malat1 through STAT3 and E2F1.
Jing Z; Liu Q; Xie W; Wei Y; Liu J; Zhang Y; Zuo W; Lu S; Zhu Q; Liu P
Cell Signal; 2022 Apr; 92():110265. PubMed ID: 35085770
[TBL] [Abstract] [Full Text] [Related]
13. MiR-423-5p prevents malat1-mediated proliferation and metastasis in prostate cancer.
Ferri C; Di Biase A; Bocchetti M; Zappavigna S; Wagner S; Le Vu P; Luce A; Cossu AM; Vadakekolathu J; Miles A; Boocock DJ; Robinson A; Schwerdtfeger M; Tirino V; Papaccio F; Caraglia M; Regad T; Desiderio V
J Exp Clin Cancer Res; 2022 Jan; 41(1):20. PubMed ID: 35016717
[TBL] [Abstract] [Full Text] [Related]
14. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract] [Full Text] [Related]
15. Diagnostic, prognostic, and therapeutic significance of long non-coding RNA malat1 in cancer.
Goyal B; Yadav SRM; Awasthee N; Gupta S; Kunnumakkara AB; Gupta SC
Biochim Biophys Acta Rev Cancer; 2021 Apr; 1875(2):188502. PubMed ID: 33428963
[TBL] [Abstract] [Full Text] [Related]
16. [Relationship between long non-coding RNA malat1 and prostate cancer].
Zhang F; Wu CF; Luo YH; Zhou FH
Zhonghua Nan Ke Xue; 2020 Feb; 26(2):174-179. PubMed ID: 33346423
[TBL] [Abstract] [Full Text] [Related]
17. Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer.
Chou FJ; Lin C; Tian H; Lin W; You B; Lu J; Sahasrabudhe D; Huang CP; Yang V; Yeh S; Niu Y; Chang C
Cell Death Dis; 2020 Nov; 11(11):942. PubMed ID: 33139720
[TBL] [Abstract] [Full Text] [Related]
18. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract] [Full Text] [Related]
19. Exercise-mediated downregulation of malat1 expression and implications in primary and secondary cancer prevention.
Paronetto MP; Dimauro I; Grazioli E; Palombo R; Guidotti F; Fantini C; Sgrò P; De Francesco D; Di Luigi L; Capranica L; Caporossi D
Free Radic Biol Med; 2020 Nov; 160():28-39. PubMed ID: 32768573
[TBL] [Abstract] [Full Text] [Related]
20. Signaling through estrogen receptors modulates long non-coding RNAs in prostate cancer.
Nanni S; Bacci L; Aiello A; Re A; Salis C; Grassi C; Pontecorvi A; Gaetano C; Farsetti A
Mol Cell Endocrinol; 2020 Jul; 511():110864. PubMed ID: 32413384
[TBL] [Abstract] [Full Text] [Related]
[Next]
